Telangana-based ethnic apparel retailer Sai Silks Kalamandir to launch IPO on September 20

| Leave a Comment | IPO

Sai Silks Kalamandir, a Telangana-based ethnic apparel retailer, has announced that it will launch its maiden public offering (IPO) on September 20. The IPO comprises a fresh issuance of shares worth Rs 600 crore and an offer-for-sale (OFS) of 2,70,72,000 equity shares by promoter group.

The price band for the offer will be announced by the company soon. The anchor book, a part of QIB, will be opened for subscription for a day on September 18, a day before the issue opening.

Half of the public issue size has been reserved for qualified institutional buyers (QIB), 15 percent for high net worth individuals (HNIs), and the remainder 35 percent for retail investors. Of the QIB, up to 60 percent portion is set aside for anchor investors.

Sai Silks Kalamandir is one of the top 10 retailers of ethnic apparel, particularly sarees, in south India in terms of revenues and net profit in FY22. The company has a network of 54 stores in Andhra Pradesh, Telangana, Karnataka and Tamil Nadu.

The company plans to use the net proceeds from the IPO to set up 30 new stores, two warehouses, and for working capital requirements. It will also repay its debts.

Motilal Oswal Investment Advisors, HDFC Bank, and Nuvama Wealth Management are the merchant bankers for the offer, while Bigshare Services is the registrar to the issue.

The IPO is the ninth one to be launched in September. Other IPOs launched in September include Signature Global, Yatra Online, Zaggle Prepaid Ocean Services, SAMHI Hotels, R R Kabel, EMS, Jupiter Life Line Hospitals, and Ratnaveer Precision Engineering.


Related News

  • 22 Sep

    Samhi Hotels Stock Lists with 6.75% Premium, Analysts Recommend Booking Profits

    Samhi Hotels stock made a weak debut on the stock exchanges, listing at a premium of just 6.75% over the IPO price. Several analysts have recommended booking profits in the stock, citing its loss-making status and negative net worth.

  • 22 Sep

    Signature Global IPO Subscribed 11.88 Times on Final Day

    The Signature Global IPO was subscribed 11.88 times on the final day of bidding. The company will use the proceeds to repay debt and for land acquisitions and general corporate purposes. The IPO is expected to list on October 4, but this may change due to the new timeline of T+3.

  • 22 Sep

    Sai Silks IPO Oversubscribed 4.4 Times on Final Day of Bidding

    Sai Silks IPO was oversubscribed 4.4 times on the final day of bidding, with qualified institutional buyers and high networth individuals supporting the issue on closing day. The net fresh issue proceeds will be utilized by the company mainly for the setting up of 30 new stores, two warehouses, working capital requirements and repaying debts. The trading in its equity shares will commence with effect from October 4, as per the IPO schedule.

  • 22 Sep

    Pharma company Valiant Laboratories to go public on September 27

    Pharma company Valiant Laboratories is going public on September 27 at a price band of Rs 133-140 per share. The company plans to raise Rs 152.46 crore via the IPO. Proceeds will be used to fund the expenditure for setting up a manufacturing facility for speciality chemicals and for working capital requirements and general corporate purposes. Valiant Laboratories is a Mumbai-based API and bulk drug manufacturing company with a focus on Paracetamol. It is owned by the promoters including Dhanvallabh Ventures LLP, which holds 62.5 percent shareholding. Valiant Organics, the listed entity on the BSE and NSE, is the promoter of Dhanvallabh Ventures LLP with 73.15 percent stake.

  • 21 Sep

    Unihealth Consultancy makes tepid debut on NSE Emerge

    Unihealth Consultancy, a healthcare service provider, made a tepid debut on the NSE Emerge platform on September 21, listing at Rs 135, a 2.2 percent premium over its issue price of Rs 132. The stock was trading at Rs 137.30 at 11.40 am. The company has a number of positives going for it, such as its strong growth potential, its diversified business model, and its focus on the African market. However, investors who are considering investing in Unihealth Consultancy should carefully consider the company's fundamentals, the current market conditions, and their own risk appetite before making a decision.

Leave a Reply

Your email address will not be published. Required fields are marked *